Nutter Carol Purchases 875 Shares of Claritev (NYSE:CTEV) Stock

Claritev (NYSE:CTEV) SVP Nutter Carol bought 875 shares of the stock in a transaction on Tuesday, June 9th. The stock was purchased at an average price of $28.41 per share, with a total value of $24,858.75. Following the completion of the purchase, the senior vice president owned 46,941 shares of the company’s stock, valued at $1,333,593.81. This represents a 1.90% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Claritev Trading Up 8.2%

NYSE:CTEV opened at $32.18 on Friday. Claritev has a 12 month low of $11.50 and a 12 month high of $74.07. The firm has a fifty day simple moving average of $22.67 and a 200-day simple moving average of $26.64. The company has a market capitalization of $548.67 million, a P/E ratio of -1.86 and a beta of 0.77.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in shares of Claritev in the fourth quarter valued at about $25,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Claritev in the first quarter valued at about $38,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Claritev in the third quarter valued at about $42,000. Legal & General Group Plc acquired a new stake in shares of Claritev in the third quarter valued at about $45,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Claritev in the fourth quarter valued at about $45,000. Hedge funds and other institutional investors own 87.15% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Claritev in a research note on Friday, March 27th. Citigroup reaffirmed a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. UBS Group reaffirmed a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Wells Fargo & Company cut their price objective on shares of Claritev from $30.00 to $22.00 and set an “equal weight” rating for the company in a report on Thursday, March 19th. Finally, Piper Sandler set a $61.00 price objective on shares of Claritev in a report on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.67.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.